Deschloroketamine

Deschloroketamine (DCK), also known as 2-oxo-PCM, is a synthetic dissociative in the arylcyclohexylamine family. It is structurally related to ketamine but lacks the chlorine atom on the phenyl ring. The compound has appeared on the research-chemical market as a ketamine analogue, and forensic reports have confirmed its presence in biological samples and seized materials.

Chemistry

DCK retains the cyclohexanone and methylamine structure of ketamine. The main difference is the absence of the chlorine substituent on the aromatic ring, which is the origin of the name “deschloroketamine”. It is a chiral molecule and is commonly encountered as a racemate.

It is related to ketamine and 2-FDCK. The latter carries a fluorine substituent on the phenyl ring, whereas DCK has no halogen at that position.

Pharmacology

DCK is thought to act primarily as an NMDA receptor antagonist, like ketamine and other dissociative anaesthetics. Much of the early discussion of its pharmacology was based on its structure and on similarities in reported effects. Direct data remain more limited than for ketamine.

Forensic research has focused on identifying DCK and its metabolites in blood, hair and urine. A 2021 analytical study described methods for detecting DCK and related ketamine analogues in post-mortem samples, illustrating the difficulty of distinguishing these compounds in routine toxicology (Forensic Science International, 2021).

Subjective effects

The PsychonautWiki profile of deschloroketamine compares the experience more closely with ketamine and methoxetamine than with more stimulating PCP analogues. The list remains incomplete and draws largely on anecdotal reports.

Physical effects

Reported effects include sedation, pain relief, muscle relaxation, dizziness, nausea and reduced motor coordination. Some users describe bodily lightness and physical euphoria, while others experience spatial disorientation and tactile suppression. Changes in sexual response are also mentioned, although reports differ on their direction.

Dissociative effects

Dissociation is the defining feature of the reported experience. Users describe detachment from the body and surroundings, reduced tactile awareness and a sense that the environment has become distant or fragmented. More intense reports include visual disconnection and internal hallucinations.

Cognitive and visual effects

Reported cognitive effects include conceptual thinking, introspection, changes in memory and time perception, and euphoria. Confusion and difficulty organising thoughts may accompany stronger dissociation. Visual reports include optical sliding, changes in perspective and internal imagery rather than a consistent pattern of elaborate geometric visuals.

Clinical and forensic evidence

A 2020 case series described 20 analytically confirmed exposures to 2-FDCK, with DCK detected alongside it in half of the cases. The clinical effects in the group were mainly neurological and cardiovascular, but because multiple ketamine-type substances were commonly present, the findings cannot be attributed to DCK alone (Tse and colleagues, 2020).

A 2025 monograph from the Center for Forensic Science Research and Education reported that DCK had been detected in several toxicology cases and drug materials analysed by its laboratory. The document describes it as an NMDA receptor antagonist and notes that its identification in seized material has increased the need for reliable analytical reference standards (CFSRE, 2025).

Toxicity and harm potential

The acute and long-term toxicity of DCK is not fully characterised. Clinical cases involving mixtures of ketamine analogues make it difficult to determine which substance caused a particular symptom. The available evidence does not establish a reliable toxic range or a complete interaction profile.

As with other NMDA antagonists, repeated use is associated in user reports with tolerance, psychological dependence and memory-related problems. These concerns have not been quantified in large clinical studies of DCK itself.

Related compounds

DCK is related to ketamine, 2-FDCK, methoxetamine (MXE) and other arylcyclohexylamine dissociatives. Structural similarities help explain their shared NMDA-related effects, but do not establish identical pharmacological or toxicological profiles.